Ets proteins constitute a family of conserved sequencespecific DNA-binding proteins and function as transcription factors. ETS1 plays important roles in differentiation, lymphoid cell development, invasiveness and angiogenesis. Such diverse roles of ETS1 are likely to be dependent on its associated proteins. A yeast twohybrid screen was conducted and here we describe a novel ETS1 interacting protein designated as ETS1-associated protein II (EAPII). EAPII protein interacts with ETS1 and other Ets proteins (ETS2 and FLI1) both in vitro and in vivo. Indirect immunofluorescence demonstrated that EAPII is predominately localized to the nucleus of mammalian cells. EAPII negatively modulates ETS1 transcriptional activity and attenuates synergistic transactivation by ETS1 and AP-1. Significantly, re-expression of EAPII inhibits the migration of epithelial cancer cells, but does not affect cell viability. Therefore, EAPII is a novel ETS1 modulator that regulates specific aspects of the ETS1 functions.
Introduction
Ets proteins constitute a family of conserved sequencespecific DNA-binding proteins, which share an 85 amino-acid DNA-binding domain (ETS domain). Over 25 mammalian Ets family members control important biological processes, including cellular proliferation, differentiation, lymphocyte development and activation, transformation and apoptosis, by recognizing the GGA core motif in the promoter or enhancer of their target genes (Ghysdael and Boureux, 1997; Sementchenko and Watson, 2000; Sharrocks, 2001) . vEts1, the founding member of the Ets family, encodes one of the transforming proteins of the E26 virus. Cellular ETS1 plays roles in cell proliferation, differentiation, lymphoid cell development, transformation, invasiveness, angiogenesis and apoptosis (Li et al., 1999; Watson et al., 2002) . However, it is not yet fully understood how ETS1 controls the multiple pathways involved in these diverse biological functions. Protein-protein interactions are likely to regulate multiple ETS1 functions, including receiving cellular signals, selecting target genes, modulating the ability to bind DNA and regulating transcriptional activity and degradation (Li et al., 2000a; Verger and Duterque-Coquillaud, 2002) . For example, multiple Pax proteins are capable of recruiting Ets proteins to a Pax/Ets composite site in the early Bcell-specific mb-1 promoter (Fitzsimmons et al., 1996; Wheat et al., 1999) . Therefore, ETS1 DNA-binding affinity, target selection and transactivation is dependent upon specific protein partnerships and provides a plausible mechanism for cell-type or tissue-specific differences in activity.
Many transcription factors such as AP-1, NFkB and Pax family members, which are activated by different cellular signals, cooperate with ETS1 and provide combinatorial control over the specificity of ETS1 function (Li et al., 2000a) . This type of signal-specific control is a characteristic property of Ets family members. Adjacent ETS1 and AP-1 binding sites have been found on a large number of promoter/enhancer elements for such genes as cytokines and matrix metalloproteinases (MMPs); and adjacent or overlapping binding sites for ETS1 and NFkB can be found on many lymphoid or viral genes, including the HIV-I enhancer (Holzmeister et al., 1993; Seth et al., 1993; Kramer et al., 1995; Nimer et al., 1996; Thomas et al., 1997; Gri et al., 1998; Westermarck and Kahari, 1999) . The predominant biological functions of ETS1 in different cells and tissues are dependent upon specific protein partnerships, which are dictated by the convergence of multiple cellular signals and allow different cells or tissues to specifically respond to identical signals. The complex and often contrasting cellular functions of ETS1 may also result from intricate combinatorial controls resulting from the convergence of multiple cellular signals onto ETS1. Pointed domain (PNT), the second-most conserved domain in the Ets family, is involved in protein-protein interaction and is responsible for receiving extracellular signals. However, it is not clear how signals can be coordinated by protein interactions in response to diverse signals including cytokines, growth factors, antigens and cellular stresses. Therefore, to identify additional proteins that may modulate ETS1 function, we initiated a study to isolate proteins based upon their interaction with the PNT domain of ETS1. The NH 2 terminus of human ETS1 containing the first 139 amino acids was chosen as bait for an yeast two-hybrid interactive screen. Previous work utilizing this screen demonstrated that ETS1 interacts with the Daxx protein, referred to as ETS1-associated protein I (EAPI) (Li et al., 2000b) . In this paper, we identify another ETS1 interacting protein, ETS1-associated protein II (EAPII). EAPII negatively modulates ETS1 transactivation and synergistic transactivation by ETS1 and AP-1 on the matrix metalloproteinase 1 (MMP1) promoter. Furthermore, association between EAPII and other Ets family members was demonstrated in vivo. While EAPII does not affect cell viability, it inhibits one important aspect of tumoregenicity, cell migration.
Results

EAPII interacts with ETS1 in yeast
We have used the yeast two-hybrid interaction trap method (Gyuris et al., 1993) to screen for proteins that interact with ETS1. Bait selection and the primary screening have been described previously (Li et al., 2000b) . Briefly, the N139-ETS1 fragment derived from the NH 2 -terminal domain of ETS1 was used as bait to screen a fetal brain cDNA expression library. Of the approximately 1 Â 10 6 transformants, 23 individual clones were identified by restriction mapping of PCR products. Eight of the 23 clones were found to encode novel proteins. One of these novel genes was named EAPI, which was subsequently identified as the Daxx gene (Yang et al., 1997; Li et al., 2000b) . Another clone pJG45-clone #8, represented by five separate identical isolates from the primary screen, contained the majority of an open-reading frame (36-362 of 362 amino acids) of a hypothetical protein. Sequence corresponding to this clone has been identified by the human genome project (Sanger Centre, Hinxton, Cambridgeshire, UK) and its coding sequence was predicted by the Ensembl analysis pipeline from a Genscan prediction (Accession number CAA21141). To verify the interaction between pJG45-clone #8 and ETS1 in yeast, the EGY48 yeast strain containing the pSH18-34 reporter and the pJG45-clone #8 was transformed with the vector LexA-ETS1-N139, the empty vector pEG202 or the negative control vector pRFHM1, encoding a DNA-binding nuclear peptide without the ability to activate transcription, respectively. b-Galactosidase activity of the reporter gene was strongly elevated by LexA-ETS1-N139, but not by the empty vector pEG202 or the negative control vector pRFHM1 ( Figure 1a ). We constructed a series of truncated ETS1 proteins using the LexA-202 vector (Li et al., 2000b) . To test the specificity of the interaction and to map the possible interaction domain(s) in ETS1, EGY48 yeast derivatives containing the pSH18-34 and the 11 pEG202 constructs encoding different ETS1 trap proteins were transformed with the library plasmid pJG45-clone #8. In all, 11 individual transformants were Figure 1 EAPII specifically interacts with ETS1 in yeast. (a) EAPII and ETS1 interact in yeast. The EGY48 yeast strain containing the pSH18-34 reporter and the pJG-45-clone #8 (encoding EAPII) was transformed with the empty vector pEG202, the LexA-ETS1-N139 vector or the negative control vector pRFHM1, respectively. Transformants were grown in Gal/CM ura À his À leu À trp À media. The galactosidase activity was measured and normalized for the same amount of protein. (b) Specificity of EAPII-ETS1 interaction in yeast. EGY48 yeast derivatives containing the pSH18-34 and the different baits were transformed with the library plasmid pJG-45-clone #8. In all, 12 individual transformants were streaked onto the master plates (SDtrp À his À GLU) and incubated at 301C until colonies formed. The layout of the trap proteins is diagrammed in the left panel. These transformants were replicated onto two plates: SD trp À his À leu À GLU, which selects for the transcription of the LexA-LEU2 reporter; and SD trp À his À leu À GAL, which selects for transcription of the LexA-LEU2 only when the library protein is induced and specifically interacts with the bait protein. Baits were LexA alone (1, pEG202 empty vector), LexA fused with the NH2-terminal 139 amino acids of ETS1 (2, pEG202-ETS1-N139), 1-328 amino acids of ETS1 (3, pEG202-ETS1-N328), 330-441 amino acids of ETS1 (4, pEG202-ETS1-C330), 282-441 amino acids of ETS1 (5, pEG202-ETS1-C282), 249-441 amino acids of EAS1 (6, pEG202-ETS1-C249); 145-441 amino acids of ETS1 (7, pEG202-ETS1-C145), 249-418 amino acids of ETS1 (8, pEG202-ETS1-249-418), or full-length ETS2 and MafB proteins (9, pEG202-Ets2; 10, pEG202-MafB), respectively. A construct without Lex A serves as the negative control (11, pEGD). Assays were performed in triplicate and repeated two times from different individual clones EAPII inhibits ETS1 transactivation and cell migration H Pei et al streaked onto the master plates (SDtrp À his À GLU) and incubated at 301C until colonies formed (Figure 1b) . Four constructs (pEG202 vector, pEG202-ETS1-N328, pEG202-ETS1-C330 and the negative control pEGD) did not transactivate the reporter. Four other constructs (pEG202-ETS1-C145, pEG202-ETS1-249-418, pEG202-ETS2 and pEG202-MafB) demonstrated transactivation independent of the presence of the prey protein (clone #8), indicating that the transactivation of the reporter may result from the intrinsic transcriptional activity of these trap proteins. The remaining three constructs (pEG202-ETS1-N139, pEG202-ETS1-C282 and pEG202-ETS1-C249) showed transactivation that was dependent on the presence of d-galactose (GAL), which induces the expression of the prey protein. pEG202-ETS1-C282 included the Ets DNA-binding domain (ETS) and its flanking bilateral inhibitory domains, while pEG202-ETS1-C249 extended further into the NH 2 -terminal end of ETS1 and included the entire exon VII region. These results demonstrated that both the NH 2 -terminal region, which includes the PNT, and amino acids 282-441 of ETS1, which includes the ETS domain, independently interacted with clone #8. Therefore, these data demonstrate that there may be multiple clone #8 interaction domains in ETS1.
EAPII distributes with tissue-specific variations
The complete open-reading frame of clone #8 was generated by RT-PCR from human T lymphocyte Jurkat cell cDNA (see Materials and methods). The sequence of clone #8 was deposited in GenBank and we named this protein EAPII, (Accession number AF201687). The predicted molecular weight of the protein was calculated to be 41 kDa. There is no significant homology to known peptides in the database. However, in vitro translated protein was found to migrate at an apparent molecular weight of 49 kDa (data not shown), probably reflecting the high level of charged amino acids (40%) in the protein. The partial brain cDNA (see above), the full-length Jurkat cDNA and the predicted amino-acid sequence from the human genome project (NT_007592) show 100% identity, indicating that our EAPII cDNA clones encode the wild-type protein. Analysis of the tissue distribution of EAPII mRNA was carried out using a dot blot with total RNA from multiple human tissues (Clontech, Palo Alto, CA, USA). The result showed tissue-specific variations of EAPII expression levels in both the adult and fetus. Higher expression was observed in certain organs including kidney, lung, liver, thymus, ovary, prostate, fetal lung and fetal thymus, whereas expression levels are low in the central nervous system and pancreas (Figure 2a) . Note that the high hybridization signal to bacterial DNA is likely due to the residual plasmid sequence carried in the EAPII probe (see Material and methods). A better indication of probe specificity is shown by the lack of cross hybridization with yeast RNA samples. Northern analysis showed that EAPII is encoded by a single 2.3 kb transcript in all cell lines examined, but the expression levels varied among different cell types (Figure 2b ). For example, expression levels of the EAPII mRNA in SKOV-3 (ovarian cancer cell line) and HUVECs (primary endothelial cells) was lower compared to other cell lines examined.
EAPII interacts with ETS1 in vitro
We showed above that both the NH 2 -terminal aminoacid region and COOH-terminal region of the ETS1 protein interacted with the nearly full-length EAPII protein (amino acids 36-362) in yeast. To further verify this interaction, a GST-EAPII fusion protein was incubated with an ETS1 [ 35 S]methionine-labeled in vitro translation product (Figure 3a ). ETS1 interacted with EAPII but not with the GST docking protein. The reverse GST-ETS1 pull-down experiment was performed using three constructs of the EAPII protein, including EAPII (full-length EAPII), EAPII DN (EA-PII104-362 aa) and EAPII N135 (EAPII1-135 aa). Compared to full-length EAPII, EAPII DN showed increased binding affinity, while EAPII N135 lost all ability to bind to EST1 (Figure 3b ). Multiple bands are seen in EAPII full-length and EAPII N135 samples but not in EAPII DN , indicating susceptible proteolytic site(s) or the presence of alternative, internal translation initiating AUG within the N-terminal domain. In any case, these alternative peptides showed similar binding affinity as their full-length counterparts. The GST-ETS1 DN lacking the amino acids 1-145 of the NH 2 -terminal region of ETS1 protein is also able to interact with EAPII (data not shown).
To further verify the interaction, protein association assays were performed by incubating GST-fusion proteins immobilized by glutathione-sepharose beads with cell lysates from transiently transfected COS1 cells. Equivalent amounts of input of GST or GST-EAPII protein were verified by Ponceau S staining (data not shown). The level of ETS1 protein expression was monitored by Western blot of the input extracts ( Figure 3c ). GST-EAPII fusion protein, but not GST alone, binds ETS1 protein from the lysates of ETS1-transfected cells (Figure 3c ). We also compared the binding affinity of EAPII with full-length ETS1 and p42-ETS1, a variant form of ETS1 lacking 87 amino acids from 244 to 331 that contain a self-inhibitory domain (Koizumi et al., 1990; Skalicky et al., 1996) . A greater amount of p42-ETS1 protein was bound by GST-EAPII compared to full-length ETS1 even though similar amounts of p42-ETS1 and ETS1 protein were incubated in the reaction (Figure 3d ).
EAPII interacts with ETS1 and other Ets family members in vivo
To assess further the potential physiological significance of this EAPII-ETS1 association, we examined whether the two proteins are associated in vivo by coimmunoprecipitation assay. Whole-cell lysates were prepared from Jurkat cells, which express both ETS1 and EAPII proteins endogenously, and immunoprecipitated with a monoclonal antibody against EAPII (42-C). The pre-sence of EAPII in Jurkat is confirmed by detection with a polyclonal anti-EAPII antibody ( Figure 4a ). ETS1 could be coprecipitated by 42-C, but not by the nonspecific mouse IgG (Figure 4b ). This association was also demonstrated in SK-HEP-1 cells (data not shown), which also express both ETS1 and EAPII proteins. Since EAPII can interact with the PNT domain and ETS domain of ETS1 (Figure 1b) , this suggested the possibility that EAPII can also interact with other Ets family members. Indeed, EAPII is associated with ETS2 ( Figure 4c ) and FLI1 ( Figure 4d ) in Jurkat cell extracts. Such association is not promiscuous, however, since EAPII does not interact with SP1, a transcription factor with C2H2-type zinc-finger structure (Narayan et al., 1997) (Figure 4e ).
Both ETS1 and EAPII are localized in the nucleus
As a transcription factor, ETS1 binds unique DNA sequences with a core GGAA/T and is localized in the nucleus. Colocalization of proteins not only gives an indication of possible interaction in vivo, but also provides clues for identifying the biological significance of the interaction. In SK-HEP-1 cells, another cultured cell line that expresses EAPII and ETS1, both proteins are present in the nucleus, although there appears to be some low-level presence in the cytoplasm of both proteins ( Figure 5A ). To ensure that this endogenous localization is not an artefactual result from the nonspecific detection of other proteins by our antibodies, we also examined the distribution of exogenously expressed protein in different types of cells. We had previously determined by Western blot (data not shown) that MCF7 (breast carcinoma cell line) and SKOV-3 (ovarian carcinoma cell line) expressed very low to nondetectable levels of EAPII, although they produce appreciable amounts of EAPII transcripts (Figure 2b ). These cells also express very low levels of endogenous ETS1 ( Figure 5B ). SKOV-3 cells (e-h) and MCF7 cells (i-l) were transiently transfected with FLAG-EAPII and ETS1. Detection of EAPII was performed utilizing an antibody directed against FLAG. Thus, only the exogenously expressed EAPII protein was detected. FLAG-EAPII was localized exclusively in the nucleus of MCF7 cells, while it was in both the nucleus and cytoplasm of SKOV-3 cells. ETS1 appeared in the nucleus of both types of cells (f, j). Image merging demonstrated that FLAG-tagged EAPII and ETS1 are both localized in the nucleus (h, i).
EAPII represses the transcriptional activity of ETS1 and the synergistic action of ETS1 and AP-1
In order to identify the functional significance of the interaction between EAPII and ETS1, the effect of EAPII on ETS1-dependent transcriptional activity was measured utilizing a luciferase reporter gene driven by the MMP1 promoter (Rutter et al., 1998) . MMP1 has been shown to be a relevant target gene for ETS1 and is involved in the processes of tumor invasion and metastasis (Iwasaka et al., 1996; Oda et al., 1999) . Constructs containing the MMP1 promoter driving the SKOV-3 (e-h) and MCF7 (i-l) cells were transiently transfected with FLAG-tagged EAPII and ETS1. The cells were treated with the polyclonal antibody against ETS1 (C20) and monoclonal antibody against FLAG (M5). ETS1 (f, j) was stained with rhodomine (red color), FLAG-tagged EAPII (e, i) with fluorescein (green) and the nucleus with the DNA intercalating dye DAPI g, k). The merged panels are superimposed images of ETS1, FLAG-EAPII and the nucleus (h, l). The green and red colors in the superimposed images result in a yellow color EAPII inhibits ETS1 transactivation and cell migration H Pei et al luciferase reporter were transiently cotransfected in COS-1 cells either with ETS1 or EAPII alone or with ETS1 and increasing amounts of EAPII (Figure 6a) . ETS1 increased the transcriptional activity of the reporter by about 25-fold over background, while EAPII alone did not significantly modulate the transcriptional level of the reporter. However, transcriptional activity of ETS1 was repressed by coexpression of the EAPII protein in a dose-dependent manner. GST pull-down experiments have indicated that EAPII protein lacking the NH2-terminal 104 amino acids (EAPII DN ) interacts with ETS1 more strongly than the full-length EAPII protein, while the protein containing only the NH 2 terminus (EAPII N135 ) was unable to interact with ETS1 (Figure 3b) . Interestingly, the differential interaction ability of these proteins correlates well with their ability to suppress ETS1-mediated transcriptional activity (Figure 6b) .
Cooperation among Ets family members and other transcriptional factors has been demonstrated for a large number of enhancers or promoters containing overlapping controlling elements. One prominent example is the collaboration between ETS1 and AP-1 in the transcriptional regulation of MMPs (Wasylyk et al., 1990; Bassuk and Leiden, 1995) . We therefore examined whether EAPII can suppress the synergistic effect of ETS1 and AP-1 on the MMP1 promoter. Results from Figure 6c (lane 11) showed that cotransfection of ETS1 and AP-1 (c-jun plus c-fos) resulted in over 170-fold transactivation in contrast to the B25-30-fold activation induced by ETS1 alone (Figure 6a ). This synergistic transactivation was significantly reduced by the expression of EAPII in a dose-dependent manner. This suppressor effect is likely mediated through ETS1 as EAPII has no significant effects on the activation by AP-1 alone (Figure 6c, lanes 7-10) .
EAPII does not inhibit ETS1 DNA binding
The ability to bind DNA is critical for transactivation by a transcription factor. To determine whether EAPII regulates the DNA-binding ability of ETS1, nuclear extracts were prepared from transiently transfected COS-1 cells and electrophoretic mobility shift assays (EMSA) were performed using an oligonucleotide that contains a consensus ETS-binding sequence (EBS). ETS1 binds to the EBS probe (Figure 7 , lanes 3 and 13) and a supershift appears upon addition of anti-ETS1 C20 antibody (lane 6), but not in the lane with control IgG (lane 12). EAPII alone does not bind to the EBS oligonucleotide (lanes 2, 5, 8 and 11). However, addition of EAPII-specific antibody (42-C) to ETS1-containing extracts produces a light supershift band with a concomitant decrease of the ETS1-DNA complex 
EAPII inhibits cell migration in epithelial cancer cells
What is the biological significance of the EAPII-ETS1 interaction? ETS1 as an oncogene has been shown to affect cellular growth properties as well as cell motility (Iwasaka et al., 1996; Chen et al., 1997; DelannoyCourdent et al., 1998) . In the course of our studies, we did not observe any consistent changes in EAPIItransfected cells in various growth conditions and substrates (data not shown). This was further analysed using DU145, a metastatic cancer cell line expressing a high level of ETS1. It has been shown that the DU145-transformed phenotype can be reverted by expressing a dominant negative mutant common to the ETS1/2 DNA-binding domain (Sementchenko et al., 1998) . Indeed, DU145 did not show growth inhibition when transiently infected with EAPII by adenoviral vector Ad-EAPII (Figure 8 ). Instead, we observed a striking inhibitory effect of EAPII on the migratory potential of these cells. The cells were infected with Ad-EAPII or control GFP at 0, 10 25, 50 and 100 multiplicity of infection (MOI). A significant inhibition of cell migration was observed at 24 h in the cells infected with Ad-EAPII, but not in those infected with green fluorescent protein (GFP) (Figure 8 ]-dCTP-labeled double-stranded oligonucleotide probe containing an ETS1 consensus site, was added and the incubation was continued for 30 min. The mixtures were resolved by PAGE and visualized using autoradiography. Arrowheads mark the protein-DNA complex specifically in the presence of ETS1. Supershifted complex are indicated by brackets. Different amounts of unlabeled probes (cold probe) were added 20 min before the addition of the labeled probes Therefore, at least in metastatic cells such as DU145, the biological effect of EAPII on ETS1 is specific for cell migration but not proliferation.
Discussion
We identify and characterize a novel protein, EAPII, that interacts with ETS1 both in vitro and in vivo. Coimmunoprecipitation and colocalization strongly suggest that EAPII and ETS1 physically associate in vivo (Figures 1, 3 and 4) . The influence of such interaction on ETS1 function was assessed using a known ETS1 target gene promoter MMP1, which requires the synergistic functions of ETS1 and AP-1 for optimal transactivation. For example, ETS1 or AP-1 alone induces MMP1 promoter activity by 25-or 50-fold, respectively, whereas ETS1 and AP-1 combinatorial action activates the promoter by B175-fold ( Figure 6 ). We show that while EAPII by itself has no effect on the MMP1 promoter activity, it can block the transactivation by ETS1 alone to a moderate extent (up to B50%). By contrast, a significant inhibitory effect (up to B90%) is observed on the synergistic actions of ETS1 and AP-1. Importantly, EAPII has little or no effect on AP-1 alone. These results indicate that EAPII may inhibit ETS1 activity by interfering with its interaction with a coactivators, at least in the case of MMP1 transcription.
Since EAPII affects cofactor interaction of ETS1, we reason that EAPII, unlike other ETS1 inhibitory factors such as Daxx (Li et al., 2000b) , should not necessarily affect the DNA-binding ability of ETS1. This is indeed the case. We show that although EAPII is associated with the ETS1-DNA complex, its presence does not reduce the DNA-binding affinity of ETS1 (Figure 7 ). Taken together, our analyses indicate that EAPII is a negative modulator of ETS1 activity and that in the context of MMP1 transcription, the mechanism is likely mediated by inhibiting interaction with coactivators such as AP-1.
Expression of EAPII is tissue specific (Figure 2a) . Notably, higher levels of EAPII are detected in organs where ETS1 is known to play a physiological role (thymus) or has been implicated in tumor formation and invasion (liver, ovary and thyroid) (Ito et al., 2000; Ozaki et al., 2000; Davidson et al., 2001; de Nigris et al., 2001) . This may suggest that EAPII, as a cellular modulator of ETS1 activity, is needed where ETS1 is highly expressed. Interestingly, EAPII expression is low in several cancer-derived cell lines, including ovarian cancer (SKOV-3) and cervical cancer (Hela). We should note, however, that the EAPII expression pattern discussed above is based on mRNA levels, which do not always correlate with protein levels. Perhaps EAPII function is reduced during cancer progression, which leads to unregulated ETS1 activity. It will be valuable to test whether altered EAPII-ETS1 association is correlated with specific pathophysiological conditions in these tissues.
As a first step toward elucidating the biological and pathological significance of EAPII-ETS1 interaction, we examined two specific aspects of the ETS1 functions. Interestingly, EAPII does not affect the proliferative rate of the ETS1-expressing metastatic cell line DU145; instead, EAPII inhibits the migratory potential of these cells (Figure 8 ). The significance of these observations is twofold. First, the inhibitory effect of EAPII on ETS1 is apparently specific and selective, indicating that EAPII may affect a subset of the ETS1 cofactors. Second, EAPII may prove to be an important modulator of the late tumorigenic event such as metastasis.
The interacting domains in ETS1 are independently located within the ETS1 N-terminus (1-139) and the COOH-terminus (282-441), which include the region of the PNT domain (54-138 aa) and the ETS domain (331-415 aa), respectively. Since the ETS and PNT domains represent the most conserved regions in this transcription factor family (Ghysdael and Boureux, 1997; Graves and Petersen, 1998), we predicted that EAPII might also interact with other Ets family members. Consistent with this hypothesis, at least two other Ets factors, ETS2 and FLI1, also associate with EAPII in Jurkat cells (Figure 4) . We demonstrated that EAPII did not interact with SP1 and did not directly interfere with the transcriptional activity of AP-1. It remains to be tested whether EAPII is a specific modulator of Ets factors and how restricted this specificity is within the Ets family. On the other hand, Ets family members have been shown to control diverse biological functions and have unique tissue distribution (Maroulakou and Bowe, 2000; Remy and Baltzinger, 2000) . Additional elucidation of possible functional partnerships between EAPII and these Ets transcription factors will give additional insight into how these Ets members are regulated in certain developmental stages and in specific tissues.
It also remains to be elucidated whether EAPII itself is regulated by growth factors or environmental cues. The EAPII interacting regions of ETS1 includes the PNT and an adjacent mitogen-activated protein (MAP) kinase phosphorylation site. This region is the docking site for transient ERK2-ETS1 complex formation. MAP kinase phosphorylation, in response to Ras signaling, regulates the transactivation function of a subset of Ets family members including ETS1 and ETS2 (Seidel and Graves, 2002) . It is possible that EAPII represses ETS1 transactivation by interfering with this pathway. EAPII was also independently identified as TTRAP (Pype et al., 2000) , which is associated with the cytoplasmic domain of CD40, a member of the tumor necrosis factor receptor family. TTRAP inhibits the transcriptional activation of NFkB induced by CD40 or phorbol 12-myristate 13-acetate. These factors also induce ETS1 transactivation and the synergism between ETS1 and NFkB is well documented. Although we show that EAPII is predominately a nuclear protein, in certain cellular contexts, EAPII is also localized in the cytoplasm ( Figure 5 and data not shown). The differential localization of EAPII implies that EAPII may be a mediator between extracellular signals and nuclear transcriptional factor(s). EAPII may represent a novel component in signal transduction processes that regulate eukaryotic gene expression in response to extracellular or intracellular signals.
Materials and methods
Two-hybrid system
The interaction trap assay system and a human fetal brain cDNA library were kindly provided by Dr Roger Brent (The Molecular Sciences Institute, Berkely, CA, USA). Bait construction and library screening have been described previously (Li et al., 2000b) . Briefly, the N-terminal 139 amino acids of ETS1 were used as bait and a human fetal brain cDNA library was constructed using the yeast vector pJG-45, which contains a B42 activation domain and allows for the fusion of proteins to its COOH terminus. All experiments were performed in the yeast reporter strain EGY48 (MATa leu2 
Cloning and plasmid construction
Proofreading PCR (Pfu, Stratagene) was used to amplify a 1417 bp fragment from human T lymphocyte Jurkat cell cDNA by the forward primer, 5 0 AGCCGCGCG-TTGGCCTCCTGTTAAGCTTAAAG3 0 and reverse primer, 5 0 ATCCAGCTGGCAGCTATAAGCACCGT3 0 . The product was digested by HindIII and EcoRI and inserted into pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). The plasmid generated above (EAPII/pcDNA3.1) expresses the full-length EAPII protein in mammalian cells. Deletion constructs of EAP1I DN (105-362 aa residues of EAPII) were generated by inserting the PCR fragment into the pcDNA3.l vector with blunt NcoI/Xbal sites. This PCR fragment was amplified from EAPII/cDNA3.1 by a forward primer 5 0 CAGCAAGAAAAT-GGCACCATGGTCTCT3 0 and a T3 reverse primer. EAPII N135 (1-135 aa residues of EAPII) was generated by digestion of EAPII/pcDNA3.1 with XhoI and followed by religation. The blunt Bsu36I/EcoRI fragment of EAPII/ pcDNA3.1 was inserted into the blunt HindIII and EcoRI sites of pCMV-FLAG-2 vector to generate FLAG-EAPII, which expresses a FLAG-tagged EAPII protein (21-362 aa). Plasmid constructs of GST-ETS1 were described previously (Li et al., 2000b) . Full-length EAPII was amplified from EAPII/cDNA 3.1 using forward primer 5 0 TGCAGAGGCGG-CAGGACCATGGA3 0 and reverse primer 5 0 CACAGCAAA-CCAAGCTTTCCAGAAG3 0 . This fragment was digested by NcoI/HindIII and inserted into 2TK2 vector (Li et al., 2000b) to generate GST-EAPII. The probe used in the Northern dot blot was prepared by releasing the full-length EAPII from EAPII/pcDNA 3.1 plasmid with the NcoI and labeled with [a-32 P]dCTP by a standard random primer labeling method. A short (B300 bp) plasmid segment was thus included in the probe.
Indirect immunostaining
Cells were grown on glass 35 mm dishes and fixed in PBS containing 4% paraformaldehyde and 0.5% Triton X-100 for 30 min at room temperature. The cells were then washed twice with PBS, and nonspecific binding was blocked for 25 min with 3% bovine serum albumin (BSA) and 10% fetal bovine serum in PBS. The cells were then incubated with affinity-purified anti-FLAG M5 monoclonal antibody (Eastman Kodak, New Haven, CT, USA) or anti-ETS1 polyclonal antibody (C-20; Santa Cruz) for 1 h at room temperature, and washed five times with PBS, followed by incubation with fluoresceinconjugated anti-mouse IgG (Pierce, Rockford, IL, USA) for FLAG-and rhodamine-conjugated anti-rabbit IgG (Pierce, Rockford IL, USA) for ETS1 C-20 polyclonal antibody for 1 h, respectively. The cells were then washed four times with PBS containing 0.02% 4', 6-diamidino-2-phenylindole (DAPI) to stain the nucleus, and the coverslips were mounted with Gel/ Mount aqueous mounting medium (Fisher, Pittsburgh, PA, USA) and observed using a fluoresent microscope.
GST pull-down assays
The GST fusion proteins were purified as described in the manufacturer's protocol (Pharmacia, Peapack, NJ, USA). 35 S-labeled proteins were obtained by in vitro translation reactions (TNT-coupled reticulocyte lysate system, Promega, Madison, WI, USA). DNA of 2 mg was used in the presence of complete amino-acid mix with T7 RNA polymerase as per the manufacturer's protocol. GST fusion protein (2-5 mg) was bound to glutathione-agarose beads and incubated with 35 S-labeled protein (5 ml), in 0.2 ml binding buffer (20 mm HEPES pH 7.6, 3 mm MgCl 2 , 0.1 mm EDTA, 0.1% Tween-20, 10% glycerol, 1 mm DTT, 0.2 m KC1, 2% BSA). The mixture was incubated by rocking for 2 h at 41C. The glutathione-agarose beads were washed four times in binding buffer (without BSA), resuspended in 20 ml of SDS sample buffer, and the proteins were released from the beads by boiling for 5 min The proteins were analysed by 10% SDS-PAGE and autoradiography.
Cell lines, transfections and transient reporter assays COS-1, the human ovarian cancer cell line SKOV-3 (ATCC-HTB-77) and the breast cancer cell line MCF7 (ATCC-HTB-22) were used in these experiments. Transient transfections were carried out using Fugene VI (Qiagen, Valencia, CA, USA) as per the manufacturer's directions. For reporter assays, cells were seeded in 24-well plates 24 h prior to transfection. Equal amounts of DNA were maintained in each transfection by addition of pcDNA3.1 vector. Cells were harvested 24 h after transfection and luciferase activity was measured by a luciferase assay kit (Promega). Preparation of cell lysates and reporter assays were carried out as per the manufacturer's protocols. Equivalent amounts of cell protein extract were used for the transient reporter assay. All transfections were performed at least three times in duplicate or triplicate. pGL3-MMP1 was used as reporter gene in the transient transfection assays.
Western blots
Western blots were developed by enhanced chemiluminescence. Anti-EAPII rabbit polyclonal antibody (220) and monoclonal antibody (42-C) were raised against full-length EAPII from GST-EAPII after thrombin cleavage. Antibodies against ETS1 (c-20, sc350), ETS2 (C20, sc351), FLI (C19, sc356) and SP1 (PEP2, sc59) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and a control mouse IgG (X0931) from DAKO (Glostrup, Denmark).
Electrophoretic mobility shift assays
EMSA was performed as follows. The consensus sequence oligonucleotides (Fisher et al., 1991) : GATCTCGAGCCG-GAAGTTCGA and complement were synthesized, prepared in double-stranded form, and end labeled with [a-32 P]dCTP by Klenow enzyme. DNA (10-20 fmol) was mixed with 5 ml of nuclear extracts (5 mg of protein), 1.2 mg of poly(dI-dC), and 2 ml of 10 Â reaction buffer (100 mm Tris-HCl, 25 mm KCl, 10 mm EDTA, 50 mm dithiothreitol, 0.5% NP40 and 10 mg/ml BSA). Water was added to each reaction to bring to a final volume of 20 ml and the mixture was incubated for 30 min at room temperature. Reaction products were separated by 4% PAGE for 3 h in 0.25 Â Tris-borate-EDTA running buffer at 200 V and visualized by autoradiography.
Recombinant adenoviral constructs and infection
The adenoviral vector was constructed according to the described methods developed by He et al (1998) . Ad-GFP, which carries the GFP under the control of the cytomegalovirus (CMV) promoter, was used as control virus. Ad-EAPII carries both the EAPII and GFP genes, each under the control of separate CMV promoters. The full-length EAPII cDNA was obtained from EAPII/pCDNA3.1 by a HindIII/XbaI double digestion and inserted into pAdTrack-CMV (from Dr Bert Vogelstein, Howard Hughes Medical Institute and The Johns Hopkins Oncology Center) and the resulting shuttle vector (pAdTrack-CMV-EAPII) was linearized by PmeI digestion and cotransformed with adenovirus backbone vector pAd-Easy-1 into recombination-competent E. coli strain BJ5183. Recombinant adenovirus vectors containing EAPII coding sequence were identified by enzyme digestion and western blot. The recombinant viruses were prepared as hightiter stocks through propagation in 293 cells. For the migration assay, Ad-EAPII viral particles were added to the cell suspension at indicated MOI before seeding on the plates.
Cell migration and viability assay
Cell migration experiments were carried out using modified Boyden chambers consisting of Transwell membrane filter inserts (polycarbonate membranes with 8-mm pore size) in 24-well tissue culture plates (Corning Costar Corp., Cambridge, MA, USA). The bottom surfaces of the Transwell membranes were coated with 5 mg/ml fibronectin (Collaborative Biomedical Products, Bedford, MA, USA). Cells (5 Â 10 4 ) in 250 ml of medium were added to each Transwell chamber containing 600 ml of medium. Cells were allowed to migrate for 24 h at 371C in the presence of 5% CO 2 and then fixed with absolute ethanol and subsequently stained with 0.5% crystal violet at room temperature. Cells that had not migrated were removed by wiping the top of the membrane with a cotton swab. The stained cells in six randomly chosen fields per filter were counted under a light microscope at Â 200 magnification. Cell viability was carried out using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, from Sigma) assays as previously described (Li et al., 1999) .
